journal
MENU ▼
Read by QxMD icon Read
search

Neurology® Neuroimmunology & Neuroinflammation

journal
https://www.readbyqxmd.com/read/28804745/dramatic-rebounds-of-ms-during-pregnancy-following-fingolimod-withdrawal
#1
Giovanni Novi, Angelo Ghezzi, Matteo Pizzorno, Caterina Lapucci, Fabio Bandini, Pietro Annovazzi, Giovanni L Mancardi, Antonio Uccelli
No abstract text is available yet for this article.
September 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28804744/reduced-rich-club-connectivity-is-related-to-disability-in-primary-progressive-ms
#2
Jan-Patrick Stellmann, Sibylle Hodecker, Bastian Cheng, Nadine Wanke, Kim Lea Young, Claus Hilgetag, Christian Gerloff, Christoph Heesen, Götz Thomalla, Susanne Siemonsen
OBJECTIVE: To investigate whether the structural connectivity of the brain's rich-club organization is altered in patients with primary progressive MS and whether such changes to this fundamental network feature are associated with disability measures. METHODS: We recruited 37 patients with primary progressive MS and 21 healthy controls for an observational cohort study. Structural connectomes were reconstructed based on diffusion-weighted imaging data using probabilistic tractography and analyzed with graph theory...
September 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28761906/mri-evaluation-of-thalamic-volume-differentiates-ms-from-common-mimics
#3
Andrew J Solomon, Richard Watts, Blake E Dewey, Daniel S Reich
OBJECTIVE: To determine whether MRI evaluation of thalamic volume differentiates MS from other disorders that cause MRI white matter abnormalities. METHODS: There were 40 study participants: 10 participants with MS without additional comorbidities for white matter abnormalities (MS - c); 10 participants with MS with additional comorbidities for white matter abnormalities (MS + c); 10 participants with migraine, MRI white matter abnormalities, and no additional comorbidities for white matter abnormalities (Mig - c); and 10 participants previously incorrectly diagnosed with MS (Misdx)...
September 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28761905/frequencies-of-neuronal-autoantibodies-in-healthy-controls-estimation-of-disease-specificity
#4
REVIEW
Katharina Lang, Harald Prüss
OBJECTIVE: To provide an extensive overview on the prevalence of antibodies against neuronal surfaces (neuronal surface antibody [NSAb]) in healthy participants and disease controls. METHODS: We searched the PubMed database (1974 to October 2016) for studies that analyzed frequencies of 22 different NSAbs in serum or CSF and included controls. Antibody prevalence was calculated for patients with NSAb-mediated disease and controls, including healthy participants, and those with neurologic and nonneurologic diseases...
September 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28761904/iglon5-antibody-neurological-accompaniments-and-outcomes-in-20-patients
#5
Josephe A Honorat, Lars Komorowski, Keith A Josephs, Kai Fechner, Erik K St Louis, Shannon R Hinson, Sabine Lederer, Neeraj Kumar, Avi Gadoth, Vanda A Lennon, Sean J Pittock, Andrew McKeon
OBJECTIVE: To describe the phenotypes, treatment response, and outcome of IgLON5 autoimmunity. METHODS: Archived serum and CSF specimens from 367 patients known to harbor unclassified antibodies which stained neural synapses diffusely (mimicking amphiphysin-IgG) were reevaluated by indirect immunofluorescence assay (IFA) using a composite of mouse tissues and recombinant IgLON5-transfected cell-based assay (CBA, Euroimmun). RESULTS: Available specimens (serum, 25; CSF, 9) from 26/367 patients (7%) had identical IFA appearance and robust IgLON5 CBA positivity...
September 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28761903/natalizumab-granule-cell-neuronopathy-fdg-pet-in-diagnosis-and-immune-reconstitution-with-g-csf
#6
Salwa Kamourieh, Kohilan Gananandan, Joel Raffel, Richard Nicholas
No abstract text is available yet for this article.
September 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28761902/glucocorticoid-associated-blood-glucose-response-and-ms-relapse-recovery
#7
Myla D Goldman, Scott Koenig, Casey Engel, Christopher R McCartney, Min-Woong Sohn
OBJECTIVE: To determine the relationship between MS relapse recovery and blood glucose (BG) response to IV methylprednisolone (IVMP) treatment. METHODS: We retrospectively identified 36 patients with MS admitted for IVMP treatment of acute relapse who had adequate data to characterize BG response, relapse severity, and recovery. The relationship between glucocorticoid-associated nonfasting BG (NFBG) and relapse recovery was assessed. RESULTS: Highest recorded nonfasting BG (maximum NFBG [maxNFBG]) values were significantly higher in patients with MS without relapse recovery compared with those with recovery (271 ± 68 vs 209 ± 48 mg/dL, respectively; p = 0...
September 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28740856/opsoclonus-myoclonus-syndrome-during-rituximab-treatment-for-autoimmune-autonomic-ganglionopathy
#8
Oana M Dumitrascu, Andrew McKeon, Leslie Zuniga, Marie F Grill, Brent P Goodman
No abstract text is available yet for this article.
September 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28680918/lipoic-acid-pharmacokinetics-at-baseline-and-1-year-in-secondary-progressive-ms
#9
Frank Bittner, Charles Murchison, Dennis Koop, Dennis Bourdette, Rebecca Spain
No abstract text is available yet for this article.
September 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28680917/predicting-long-term-disability-outcomes-in-patients-with-ms-treated-with-teriflunomide-in-temso
#10
Maria Pia Sormani, Philippe Truffinet, Karthinathan Thangavelu, Pascal Rufi, Catherine Simonson, Nicola De Stefano
OBJECTIVE: To predict long-term disability outcomes in TEMSO core (NCT00134563) and extension (NCT00803049) studies in patients with relapsing forms of MS treated with teriflunomide. METHODS: A post hoc analysis was conducted in a subgroup of patients who received teriflunomide in the core study, had MRI and clinical relapse assessments at months 12 (n = 552) and 18, and entered the extension. Patients were allocated risk scores for disability worsening (DW) after 1 year of teriflunomide treatment: 0 = low risk; 1 = intermediate risk; and 2-3 = high risk, based on the occurrence of relapses (0 to ≥2) and/or active (new and enlarging) T2-weighted (T2w) lesions (≤3 or >3) after the 1-year MRI...
September 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28680916/lipoic-acid-in-secondary-progressive-ms-a-randomized-controlled-pilot-trial
#11
Rebecca Spain, Katherine Powers, Charles Murchison, Elizabeth Heriza, Kimberly Winges, Vijayshree Yadav, Michelle Cameron, Ed Kim, Fay Horak, Jack Simon, Dennis Bourdette
OBJECTIVE: To determine whether lipoic acid (LA), an endogenously produced antioxidant, slowed the whole-brain atrophy rate and was safe in secondary progressive MS (SPMS). METHODS: Patients with SPMS aged 40-70 years enrolled in a single center, 2-year, double-blind, randomized trial of daily oral 1,200 mg LA vs placebo. Primary outcome was change in annualized percent change brain volume (PCBV). Secondary outcomes were changes in rates of atrophy of segmented brain, spinal cord, and retinal substructures, disability, quality of life, and safety...
September 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28702477/the-case-for-autoimmune-neurology
#12
EDITORIAL
Josep Dalmau
No abstract text is available yet for this article.
July 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28680915/comparative-utility-of-disability-progression-measures-in-ppms-analysis-of-the-promise-data-set
#13
Marcus W Koch, Gary R Cutter, Gavin Giovannoni, Bernard M J Uitdehaag, Jerry S Wolinsky, Mat D Davis, Joshua R Steinerman, Volker Knappertz
OBJECTIVE: To assess the comparative utility of disability progression measures in primary progressive MS (PPMS) using the PROMiSe trial data set. METHODS: Data for patients randomized to placebo (n = 316) in the PROMiSe trial were included in this analysis. Disability was assessed using change in single (Expanded Disability Status Scale [EDSS], timed 25-foot walk [T25FW], and 9-hole peg test [9HPT]) and composite disability measures (EDSS/T25FW, EDSS/9HPT, and EDSS/T25FW/9HPT)...
July 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28680914/antiepileptic-drug-therapy-in-patients-with-autoimmune-epilepsy
#14
Anteneh M Feyissa, A Sebastian López Chiriboga, Jeffrey W Britton
OBJECTIVE: We aimed to report the pattern of usage and efficacy of antiepileptic drugs (AEDs) in patients with autoimmune epilepsy (AE). METHODS: We retrospectively studied the Mayo Clinic's electronic medical record of patients with AE in which seizures were the main presenting feature. Clinical data, including demographics, seizure characteristics, type of AED and immunotherapy used, presence of neural antibody, and treatment outcomes, were reviewed. RESULTS: The medical records of 252 adult patients diagnosed with autoimmune encephalitis and paraneoplastic disorders were reviewed...
July 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28642892/dacrystic-seizures-a-cry-for-help
#15
Avi Gadoth, Jaysingh Singh, Jeffrey W Britton, Eoin P Flanagan, Sean J Pittock
No abstract text is available yet for this article.
July 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28642891/safety-tolerability-of-the-anti-semaphorin-4d-antibody-vx15-2503-in-a-randomized-phase-1-trial
#16
Christopher LaGanke, Lawrence Samkoff, Keith Edwards, Lily Jung Henson, Pavle Repovic, Sharon Lynch, Lael Stone, David Mattson, Aaron Galluzzi, Terrence L Fisher, Christine Reilly, Laurie A Winter, John E Leonard, Maurice Zauderer
OBJECTIVE: To evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VX15/2503 in a randomized, single-dose, dose-escalation, double-blind, placebo-controlled study enrolling adult patients with MS. METHODS: Single IV doses of VX15/2503 or placebo were administered. Ten patients each were randomized (4:1 randomization ratio) into 5 ascending dose cohorts of 1, 3, 6, 10, or 20 mg/kg. Safety, immunogenicity, PK/PD, MRI, ECG, and lymphocyte subset levels were evaluated...
July 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28642890/aryl-hydrocarbon-receptor-activity-may-serve-as-a-surrogate-marker-for-ms-disease-activity
#17
EDITORIAL
Joseph J Sabatino, Scott S Zamvil
No abstract text is available yet for this article.
July 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28642889/anca-associated-vasculitis-predominantly-presenting-with-severe-myalgias
#18
Edward Bahou, Lan Zhou
No abstract text is available yet for this article.
July 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28642888/aquaporin-4-antibodies-in-patients-treated-with-natalizumab-for-suspected-ms
#19
Anna Gahlen, Anne-Kathrin Trampe, Steffen Haupeltshofer, Marius Ringelstein, Orhan Aktas, Achim Berthele, Brigitte Wildemann, Ralf Gold, Sven Jarius, Ingo Kleiter
OBJECTIVE: To evaluate (1) the frequency of aquaporin-4 antibody (AQP4-ab)-seropositive cases among patients treated with natalizumab (NAT) and previously diagnosed with MS (MS(NAT)) in a nationwide cohort, (2) the clinical course of NAT-treated AQP4-ab-seropositive neuromyelitis optica spectrum disorder (NMOSD) patients (NMO(NAT)), (3) AQP4-ab titers in NMO(NAT) and AQP4-ab-seropositive NMOSD treated with other immunotherapies (NMO(IT)), and (4) immune mechanisms influencing disease activity in NMO(NAT)...
July 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28642887/dynamic-regulation-of-serum-aryl-hydrocarbon-receptor-agonists-in-ms
#20
Veit Rothhammer, Davis M Borucki, Maria Isabel Garcia Sanchez, Maria Antonietta Mazzola, Christopher C Hemond, Keren Regev, Anu Paul, Pia Kivisäkk, Rohit Bakshi, Guillermo Izquierdo, Howard L Weiner, Francisco J Quintana
OBJECTIVE: Several factors influence the clinical course of autoimmune inflammatory diseases such as MS and inflammatory bowel disease. Only recently, the complex interaction between the gut microbiome, dietary factors, and metabolism has started to be appreciated with regard to its potential to modulate acute and chronic inflammation. One of the molecular sensors that mediates the effects of these environmental signals on the immune response is the aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor with key functions in immune cells...
July 2017: Neurology® Neuroimmunology & Neuroinflammation
journal
journal
49467
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"